MDS 2023 | Using cytogenetics to improve the diagnosis and prognosis of MDS & to predict response to treatment
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, discusses the use of cytogenetics in the diagnosis, prognosis, and treatment of myelodysplastic syndromes (MDS). Although cytogenetics is not a novel technique, Prof. Mittelman highlights that it is currently in more frequent use to improve MDS prognostication and predict response to different treatment modalities. This interview was recorded at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Research Funding; Takeda: Honoraria, Research Funding; Janssen: Research Funding; Roche: Research Funding; BMS: Research Funding; Celgene: Research Funding; Medison: Research Funding; Gilead: Research Funding.
